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To the editor:
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with
classical IPSS low or intermediate-1 MDS?
The “classical” International Prognostic Scoring System (IPSS),
based on cytogenetics, marrow blast percentage, and number of
cytopenias, has played a major role in prognosis assessment in
myelodysplastic syndromes (MDS).1 The recently published re-
vised IPSS (IPSS-R), using the same parameters, but with 5 rather
than 3 cytogenetic subgroups and new cutoff values for cytopenias
and marrow blast percentages, refines the original IPSS prognostic
value.2,3 However, its prognostic value for response to erythropoiesis-
stimulating agents (ESA) has not been assessed. We analyzed it
retrospectively in 456 IPSS low/intermediate (Int)-1–risk MDS
patients treated with ESA in France, Germany, and Italy.
Those 456 patients had serum erythropoietin (EPO),500mU/mL
and hemoglobin (Hb)<10 g/dL and had received ESA (EPO alfa or
b 40 000-60 000 IU/week, or darbepoetin 150-300 mg/week) for at
least 12 weeks. In addition to IPSS-R parameters, age, sex, serum
EPO level, serum ferritin (SF), red blood cell (RBC) transfusion
requirement before ESA onset were assessed for response to ESA
(based on International Working Group 2006 criteria), and overall
survival (OS) from ESA onset. Characteristics of the 456 patients at
ESA onset are listed in Table 1. Seventy-one percent of the patients
had never received RBC transfusions, and their median Hb level was
9.3g/dL (range 7.0-10); 29% of patients had received at least 4 RBC
concentrates/8 weeks before ESA onset (with a maximum of 12
concentrates). Median SF was 357 ng/mL and serum EPO was 60
mU/mL (range 6-483). IPSS was low in 55% and Int-1 in 45% of
patients. IPSS-R was very low in 15%, low in 61%, intermediate in
19%, and high in 4% of the patients.
A total of 303 (61%) patients had an erythroid response,
including 72% and 52% of low and Int-1 risk patients, respectively
(P5 .001). Using IPSS-R, 85%, 68%, 48%, and 31% of patients had
erythroid response in the very low, low, intermediate, and high-risk
groups, respectively (P , .0001).
Other prognostic factors of erythroid response, in univariate anal-
ysis, included individual IPSS-R parameters analyzed according to
IPSS-R thresholds (Hb level, platelet count, absolute neutrophil
count, marrow blast %, cytogenetics), serum EPO level, SF
(variables tested as continuous variables), and previous RBC
transfusions. In multivariate analysis, IPSS-R, serum EPO, and SF
remained significantly associated with erythroid response (P ,
.0001, P , .0001, and P 5 .002, respectively).
Applying 1 point to each of the following unfavorable variables of
response to ESA, serum EPO .200 mU/mL (51), SF .350 ng/mL
(51), and IPSS-R (very low5 0, low5 1, intermediate5 2, and
high5 3) yielded a score ranging from 0 to 4, with response rates
of 85%, 80%, 64%, 40%, and 20%, respectively. As expected,
IPSS-R also had strong prognostic value for OS (not shown).
Thus, in this patient cohort with overall favorable prognostic
factors of response to ESA according to the Nordic score4 (ie, serum
EPO ,500 mU/mL and no or limited transfusion dependence),
IPSS-R alone, and even better, a score>3 (using IPSS-R, serumEPO,
and SF) proved useful to identifying patients with low response to
ESAwho also have worseOS5 andmay require alternative treatments.
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Table 1. Baseline patient characteristics
n 5
456
Patients,
%
Erythroid response
(IWG 2006 criteria)
Univariate
analysis P
Multivariate
analysis P
Hb, g/dL
,8 52 11 33
8-10 292 64 66
510 112 25 78 ,.0001
ANC
,0.8 42 9 55
$0.8 414 91 66 .16
Platelet count*
,50 17 3 37
50-100 58 13 57
.100 381 84 67 .01
Marrow blasts, %
#2 238 52 72
,2-,5 118 26 61
5-10 100 22 53 .0052
IPSS-R karyotype
Very good 21 5 71
Good 379 83 65
Intermediate 45 10 75
Poor-very poor 11 2 20 .008
IPSS
Low 256 55 72
Int-1 210 45 52 .001
IPSS-R
Very low 69 15 85
Low 281 61 68
Intermediate 87 19 48
High 19 4 31 ,.0001 ,.0001
Sex
Male 250 55 62
Female 206 45 68 .14
Age, years
#60 29 6 55
.60 427 94 66 .23
EPO, mU/mL
#100 306 67 75
.100 150 33 45 ,.0002
#200 393 86 75
.200 63 13 31 ,.0001 ,.0001
Serum ferritin, ng/mL
#350 224 49 72
.350 232 51 58 .001 .002
Previous RBC transfusions
No 323 71 73
Yes 133 29 55 .0005
WHO classification
RA 110 24 73
RAEB-1 69 15 50
RARS 114 25 70
RARS-T 2 0.3 100
RCMD 124 27 62
MDS WITH DEL 5q 21 5 62
MDS-U 16 4 55 .03 .71
ANC, absolute neutrophil count; IWG, International Working Group; MDS-U, MDS-unclassified; MDS WITH DEL, MDS associated with isolated del (5q); RA, refractory
anemia; RAEB-1, refractory anemia with excess blasts-1; RARS, refractory anemia with ring sideroblasts; RARS-T, refractory anemia with ring sideroblasts associated with
marked thrombocytosis; RCMD, refractory cytopenia with multilineage dysplasia; WHO, World Health Organization.
Univariate and multivariate analyses for response (IWG 2006 criteria). The variables with significant prognostic value in univariate analysis were integrated in the
multivariate analysis, excepting Hb, platelet count, IPSS-R karyotype, and % of blasts, because IPSS-R integrates already those variables. For EPO level, the 200 mUI/mL
threshold was chosen because it was the most significant in univariate analysis. Previous transfusions were not integrated in the model because they “duplicate” the Hb
variable.
*109/L.
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To the editor:
Impact of lead intoxication in children with iron deficiency anemia in low- and
middle-income countries
Recently, Pasricha et al1 reported on the control of iron deficiency
anemia in low- and middle-income countries.
The article discusses common contributory etiologies ranging
from nutritional to infectious causes for iron deficiency anemia in
the pediatric age group. Given that lead ingestion exacerbates iron
deficiency,2-4 may accelerate the cognitive injuries of iron deficiency,5
and may also confound the diagnosis of microcytic anemia, we were
surprised that the authors did not mention lead in their article.
Clune et al6 found that lead intoxication is remarkably common in
many areas in the world including those described by the authors. Our
own pilot study, conducted in a semiurban Indian setup, indicated
strikingly high prevalence rates of lead intoxication. Fifty-six percent
of the children in the age group of 0 to 6 years had a mean blood lead
level (BLL) above 5 mcg/dL, with close to 10% of children in this age
group having BLL dangerously above 15 mcg/dL.
Similar results were reported7,8 in separate moderate to large
population-based studies from different parts of India with an
average BLL in toxic ranges, well above the upper limit set by the
World Health Organization and the Centers for Disease Control
and Prevention for acceptable BLLs.9
Increased existence of hotspots of lead exposure in the South
Asian region exist, but the lack of universal lead-screening pro-
grams in the developing world underrecognizes lead poisoning as
a significant health hazard. Given the geographical overlap, it is
likely that many of the patients in the study of Pasricha et al had
concomitant lead poisoning.
Given the value of the authors’ discussion in creating aware-
ness and perhaps initiating legislation on the global level,
we think the likely contribution of lead intoxication should be brought
to the attention of investigators and public health officials.
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